Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
15 evidence topics · 12 sources
Estrogen receptor testing by immunohistochemistry
“The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HER2 testing and the distinction between immunohistochemistry 0 and 1+
“The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, while it is premature to create new result categories of HER2 expression (eg, HER2-Low, HER2-Ultra-Low), best practices to distinguish IHC 0 from 1+ are now clinically relevant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biopsy of metastatic disease and reassessment of receptor status
Biopsy guidance for bone-only metastatic presentation
“All patients with newly diagnosed lesions should have a biopsy, if clinically feasible, to confirm the presence of breast cancer and to assess the subtype of the recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biological markers (especially ER and HER2) should be reassessed at least once in the metastatic setting, even in case of a bone-only metastatic presentation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If a bone lesion is the biopsy site, it is preferable to biopsy a mixed lytic and sclerotic lesion rather than a pure sclerotic area to increase the chance of retrieving adequate high-quality cells to assess.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ASCO recommendation for ESR1 testing at recurrence or progression
ESMO recommendation for ESR1 and PI3K pathway testing
ABC8 recommendation for plasma ctDNA testing for ESR1 at progression
“The recommendation to test blood ctDNA at disease progression, provided that a targeted treatment is available, is consistent with the biology of ESR1 mutations as acquired mechanisms of endocrine resistance, their enrichment after aromatase inhibitor exposure, and the fact that plasma may better capture their polyclonal emergence than a single tissue biopsy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The recommendation to consider tissue testing when plasma is negative, and to repeat testing under continued endocrine-based therapy if the result would influence treatment choice, is clinically sound” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We do not recommend ctDNA assessment for the demonstration of disease progression, while recognizing that ctDNA is an appropriate option to detect actionable genomic alterations for treatment selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multigene panels on plasma or tissue
“now explicitly supporting the use of multigene assays performed on plasma ctDNA and/or tissue, not only to facilitate enrollment into clinical trials but also to identify clinically actionable alterations, particularly ESR1 mutations and alterations in the PIK3CA/AKT/PTEN pathway” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in particular, plasma is preferred for ESR1 testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing of tissue and liquid biopsy along the treatment course
“Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reflex TBx should be considered when ctDNA TF < 1%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Detection technologies and polyclonality of ESR1 mutations
“Sample sources include solid tissue biopsy, CTCs, and cell-free DNA (cfDNA); detection assays include next-generation sequencing (NGS) and droplet digital PCR (ddPCR), with ddPCR the most sensitive” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, subclonality, polyclonality, and distinct effects of different ESR1 mutations demonstrate the utility inherent in liquid biopsy as compared to solid tissue sampling in characterizing the tumor ecosystem.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PIK3CA testing in plasma with tissue reflex
“Candidates for a regimen with a phosphatidylinositol 3-kinase inhibitor and hormonal therapy should undergo testing for PIK3CA mutations using next-generation sequencing of tumor tissue or circulating tumor DNA (ctDNA) in plasma to determine eligibility for alpelisib plus fulvestrant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If no mutation is found in ctDNA, testing in tumor tissue, if available, should be used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote